Search research articles
Contact Us
Filters
Showing results (21-30 of 42) with videos related to
Page
of 5
Sort By:
Scientific Reports
|
April 13, 2021
Hemostasis, coagulation and thrombin in venoarterial and venovenous extracorporeal membrane oxygenation: the HECTIC study
Bruce Cartwright, Hannah M Bruce, Geoffrey Kershaw, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 12, 2024
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations
Nigel H Russell, Charlotte Wilhelm-Benartzi, Jad Othman, et al.
Blood
|
February 16, 2024
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission
Jad Othman, Nicola Potter, Adam Ivey, et al.
Blood
|
September 24, 2024
Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia
Sun Loo, Nicola Potter, Adam Ivey, et al.
Haematologica
|
February 26, 2026
Prognostic implications of myelodysplasia-related gene mutations in <i>NPM1</i>-mutated acute myeloid leukemia: a systematic review and meta-analysis
Yu-Sung Chang, Yi-Wei Lee, Chieh-Yu Liu, et al.
Blood
|
August 6, 2025
Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML
Jad Othman, Nicola Potter, Sylvie D Freeman, et al.
Journal of Thrombosis and Haemostasis : JTH
|
July 3, 2025
Growth factor independent 1B is a metabolic regulator that exerts pleiotropic effects on platelet function
Marie-Christine Morel-Kopp, Marie Levade, Lucinda Beutler, et al.
Blood
|
June 4, 2026
ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia
Christopher S Hourigan, Lisanne Beugelink, Jad Othman, et al.
Blood Advances
|
May 12, 2023
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
Jad Othman, Charlotte Wilhelm-Benartzi, Richard Dillon, et al.
The Lancet. Haematology
|
April 30, 2025
Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials
Nicola Potter, Jelena Jovanovic, Adam Ivey, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 42) with videos related to
Sort By:
Page
of 5
Scientific Reports
|
April 13, 2021
Hemostasis, coagulation and thrombin in venoarterial and venovenous extracorporeal membrane oxygenation: the HECTIC study
Bruce Cartwright, Hannah M Bruce, Geoffrey Kershaw, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 12, 2024
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations
Nigel H Russell, Charlotte Wilhelm-Benartzi, Jad Othman, et al.
Blood
|
February 16, 2024
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission
Jad Othman, Nicola Potter, Adam Ivey, et al.
Blood
|
September 24, 2024
Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia
Sun Loo, Nicola Potter, Adam Ivey, et al.
Haematologica
|
February 26, 2026
Prognostic implications of myelodysplasia-related gene mutations in <i>NPM1</i>-mutated acute myeloid leukemia: a systematic review and meta-analysis
Yu-Sung Chang, Yi-Wei Lee, Chieh-Yu Liu, et al.
Blood
|
August 6, 2025
Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML
Jad Othman, Nicola Potter, Sylvie D Freeman, et al.
Journal of Thrombosis and Haemostasis : JTH
|
July 3, 2025
Growth factor independent 1B is a metabolic regulator that exerts pleiotropic effects on platelet function
Marie-Christine Morel-Kopp, Marie Levade, Lucinda Beutler, et al.
Blood
|
June 4, 2026
ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia
Christopher S Hourigan, Lisanne Beugelink, Jad Othman, et al.
Blood Advances
|
May 12, 2023
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
Jad Othman, Charlotte Wilhelm-Benartzi, Richard Dillon, et al.
The Lancet. Haematology
|
April 30, 2025
Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials
Nicola Potter, Jelena Jovanovic, Adam Ivey, et al.
Page
of 5